Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Christopher Hourigan, MD, DPhil, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, provides an overview of the current role of measurable residual disease (MRD) testing in patients with acute myeloid leukemia (AML). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.